secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2022-10-28T23:59:59+00:00
Accession:  0001640334-22-002286
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria's DehydraTECH-CBD lowers blood pressure in 66-patient hypertension study
--------------------------------------------------------------------------------

- Systolic BP reduced up to 5.60 mmHg (p<0.001) over 5 weeks vs. placebo; no serious adverse events.
- BP reduction sustained for full study duration, exceeding cardiovascular risk reduction thresholds (4.6/2.2 mmHg).
- Additive BP lowering observed in patients already on standard antihypertensive therapy.
- Study used 225-450 mg/day DehydraTECH-CBD with zero serious adverse events and no liver enzyme changes.
- Results support planned Phase Ib IND study with FDA; full results to be submitted for peer review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033422002286/0001640334-22-002286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033422002286/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-22-002286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer